VENLO, the Netherlands, April 6, 2017 /PRNewswire/ --
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Investor Relations [email protected] John Gilardi Vice President, Head of Corporate Communications and Investor Relations 19300 Germantown Road | Germantown MD 20874 USA Phone +1-240-686-2222 | Fax +1-240-686-22238 QIAGEN-Str. 1 | 40724 Hilden Germany Phone +49-2103-29-11711 | Fax +49-2103-29-21711 Dr. Sarah Fakih Associate Director Investor Relations QIAGEN GmbH | QIAGEN-Str. 1 | 40724 Hilden | Germany Phone +49-2103-29-11457 | Fax +49-2103-29-21457
SOURCE QIAGEN N.V.
Advertisement
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) has posted its 2016 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports. QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2016 has been filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2017, a copy of which can be found on the website of the SEC at http://www.sec.gov or in the 'Financial Information' section of the 'Investors' section of our website at http://www.qiagen.com/About-Us/Investors/ . QIAGEN will provide printed copies of the 2016 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2016 Annual Report please contact: [email protected].
Advertisement
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Investor Relations [email protected] John Gilardi Vice President, Head of Corporate Communications and Investor Relations 19300 Germantown Road | Germantown MD 20874 USA Phone +1-240-686-2222 | Fax +1-240-686-22238 QIAGEN-Str. 1 | 40724 Hilden Germany Phone +49-2103-29-11711 | Fax +49-2103-29-21711 Dr. Sarah Fakih Associate Director Investor Relations QIAGEN GmbH | QIAGEN-Str. 1 | 40724 Hilden | Germany Phone +49-2103-29-11457 | Fax +49-2103-29-21457
SOURCE QIAGEN N.V.
